ライフサイエンスコーパス: ablative

1 , biochemically active, and was not androgen ablative.

2 This study examines the outcomes of ablative (131)I therapy after diagnostic studies with ei

3 d tumor characteristics and received similar ablative activities of (131)I.

4 AR repression, as evidenced by the higher AR-ablative activity of the permuted isomer 9 [( Z)-5-(4-hy

5 ral prostate (PC-3) tumors with the vascular ablative agent VEGF(121)/recombinant gelonin (rGel) stro

6 provides a proof of principle that potent AR-ablative agents could be developed through structural mo

7 optimization to develop a novel class of AR-ablative agents.

8 affold to develop a novel class of cyclin D1-ablative agents.

9 use troglitazone as a platform to design AR-ablative agents.

10 (CIN) is common, and current treatments are ablative and can lead to long-term reproductive morbidit

11 Ablative and chronic stimulation procedures targeting th

12 With increasing experience, advanced ablative and complex reconstructive procedures are now b

13 infiltration, supporting testing MYXV as an ablative and immune-enhancing therapy.

14 ncolytic virotherapy has been proposed as an ablative and immunostimulatory treatment strategy for so

15 n improved clinical efficacy for an array of ablative and non-ablative intervention techniques target

16 surgery, laser hair removal, and fractional ablative and nonablative laser procedures for patients c

17 ify areas under active investigation in both ablative and nonmyeloablative unrelated-donor stem cell

18 well tolerated, feasible, and effective for ablative and reconstructive indications with minimal com

19 common postoperative complication following ablative and reconstructive surgeries, in an animal mode

20 With current medical, ablative, and device therapies, the majority of patients

21 The patient was homozygous for an ablative APOE frameshift mutation (c.291del, p.E97fs).

22 rom atrial tachyarrhythmias between an index ablative approach of stand-alone PVI and a stepwise appr

23 Image-guided transcatheter and ablative approaches currently play an important role in

24 Many ablative approaches in or near the orifice of the pulmon

25 erly or comorbid patients, it is likely that ablative approaches will assume an increasingly central

26 vertebroplasty, and minimally invasive local ablative approaches.

27 The microprobe-mediated EA ablative capability is demonstrated in vitro in cancer c

28 trophic burn scars treated with a fractional ablative carbon dioxide (CO2) laser.

29 c resurfacing procedures, specifically fully ablative carbon dioxide laser or medium-depth chemical p

30 lity, safety, and treatment effectiveness of ablative chemoembolization (ACE) in the treatment of hep

31 Reported is an animal model of ablative CKD complicated by an ABD characterized by the

32 e disappearance of gene-modified cells after ablative conditioning may be due to an immune response.

33 rimary and secondary hosts in the absence of ablative conditioning.

34 The immune ablative (conditioning) regimen consisted of 200 mg/kg c

35 These results suggest that ablative control of the primary tumor may prolong surviv

36 p to one year after treatment were seen with ablative devices (27.8% vs. 26.1%, OR 1.09 [95% CI 0.99

37 (6,958 patients) were not improved with the ablative devices (38.9% vs. 37.4%, OR 1.06 [95% CI 0.97

38 erience from randomized trials suggests that ablative devices failed to achieve predefined clinical a

39 tal role in the +-application of these probe ablative devices.

40 All this serves to allow the delivery of ablative dose fractionation to the target capable of bot

41 A BED greater than 80.5 Gy seems to be an ablative dose of RT for large IHCCs, with long-term surv

42 uses advanced technology to deliver a potent ablative dose to deep-seated tumors in the lung, liver,

43 Although mechanisms of ablative-dose injury remain elusive, ongoing prospective

44 tinal tract by the EGLN inhibition to enable ablative doses of cytotoxic therapy in unresectable panc

45 -guided radiotherapy, now allows delivery of ablative doses of radiation to extracranial sites.

46 t is capable of enabling clinically relevant ablative doses of radiation to the upper abdomen without

47 dvances allow safe and effective delivery of ablative doses of radiation with stereotactic precision

48 ) techniques and image guidance have enabled ablative doses to be delivered to large liver tumors.

49 By providing an ablative effect noninvasively, SRS has altered the treat

50 Methylprednisolone injections are a non-ablative, effective treatment for refractory Meniere's d

51 993113 effectively inhibited the bone marrow ablative effects of 7,12-dimethylbenz[a]anthracene in vi

52 cant differences in QoL improvement across 3 ablative efficacy outcomes.

53 symptom assessment more accurately reflects ablative efficacy.

54 ent technology is limited by either a single ablative element, potentially leading to over-ablation o

55 is a strong predictor of ostial sites where ablative energy is required to electrically isolate the

56 The development of ablative energy sources has simplified the surgical trea

57 lability of improved ureteroscopes and newer ablative energy sources, endoscopic management of upper

58 s may ultimately inform target selection for ablative epilepsy surgery based on normative intrinsic c

59 We show here that a safer ablative fractional laser (AFL) can sufficiently facilit

60 This study explored ablative fractional laser (AFL) to assist 3-day to week-

61 asive pads, microneedling with dermarollers, ablative fractional laser (AFXL), non-AFXL, and no pretr

62 is briefly illuminated with a handheld, non-ablative fractional laser before the vaccine is intrader

63 EPD is based on ablative fractional laser or microneedle treatment of th

64 sis and marked shift in collagen types after ablative fractional laser resurfacing (AFR) within treat

65 ion of powder drug-coated array patches onto ablative fractional laser-generated skin MCs to deliver

66 ed, non-pulsed, non-ablative fractional, and ablative fractional lasers.

67 Currently ablative fractional photothermolysis (aFP) with CO2 lase

68 The advent of ablative fractional photothermolysis within the past dec

69 sensus is that laser treatment, particularly ablative fractional resurfacing, deserves a prominent ro

70 reported; ultrashort pulsed, non-pulsed, non-ablative fractional, and ablative fractional lasers.

71 eceived 3 monthly treatment sessions with an ablative fractionated CO2 laser.

72 a result of the unique biologic response to ablative fractionation.

73 Compared with traditional ablative HIFU, nondestructive pulsed HIFU (pHIFU) is pre

74 tic benefit in nonautoimmune models required ablative host conditioning.

75 erwent nonablative HSCT and 52 who underwent ablative HSCT (median ages, 56 and 54 years, respectivel

76 nation of nonablative low-energy FUS with an ablative hypofractionated radiation therapy results in s

77 al efficacy for an array of ablative and non-ablative intervention techniques targeting the cingulum,

78 assist in the development of techniques for ablative intervention.

79 dy testing the noninferiority of survival of ablative intravenous busulfan (IV-BU) vs ablative total

80 ssess whether survival of patients receiving ablative intravenous busulfan-based conditioning regimen

81 iterature, mechanical dermabrasion and fully ablative laser are not recommended in the setting of sys

82 Solutions include switching to ablative laser prostatectomy (which may carry higher lon

83 Laser scar therapy, particularly fractional ablative laser resurfacing, represents a promising and v

84 stin may be recommended without the need for ablative LASER therapy and before retinal detachment dev

85 Fractional ablative laser treatment provides significant, sustained

86 o those published for a series of fractional ablative laser treatments.

87 or RCM imaging, which, when combined with an ablative laser, may one day provide an efficient and cos

88 inoids, acitretin, surgery, surgical, laser, ablative laser, nonablative laser, laser hair removal, c

89 catheter created more transmural and larger ablative lesions in both normal and infarcted canine myo

90 yoballoon for small PVs, but showed narrower ablative lesions in the left atrial antrum.

91 Histologically, deeper extensions of ablative lesions into the PV were seen with 23-mm cryoba

92 we sought to assess if the use of additional ablative lesions that targeted all potential re-entrant

93 were seen with 23-mm cryoballoon, and larger ablative lesions were seen in the left atrial antrum usi

94 are usually self-limited, and correlate with ablative margin volume--except for changes in platelet c

95 dure were analyzed with respect to tumor and ablative margin volumes by using generalized estimating

96 Ablative margin volumes were predictive of changes at 0-

97 r treatment of large tumors and achieving an ablative margin within the untreated tissue surrounding

98 rsible electroporation (IRE) is a nonthermal ablative method based on the formation of nanoscale defe

99 Cryoablation is the most evaluated probe ablative method for the treatment of small renal masses.

100 l, IRE proved to be a fast, safe, and potent ablative method, causing complete tissue death by means

101 Our studies establish ablative methods that provide the tissue specificity aff

102 udies show success rates comparable to other ablative modalities for the treatment of Barrett's esoph

103 The integration of surgery or ablative modalities is often employed, particularly when

104 The specific ablative modalities of radiofrequency ablation, microwav

105 inct when compared with conventional thermal ablative modalities.

106 c, and immunologic responses between the two ablative modalities.

107 ta addressing the oncologic efficacy of this ablative modality are now available.

108 scopic spray cryotherapy is a relatively new ablative modality for the treatment of gastrointestinal

109 Endoscopic spray cryotherapy is a promising ablative modality for treatment of Barrett's esophagus a

110 The phospho-ablative mutation S344A did not have significant effect

111 Preparative regimens were ablative (n = 7) and nonablative (n = 3).

112 ain stimulation (DBS) has virtually replaced ablative neurosurgery for use in medication-refractory m

113 ed to recipient BALB/c mice conditioned with ablative or nonmyeloablative approaches.

114 dysplastic areas, (3) patients that receive ablative or surgical therapy require endoscopic follow-u

115 % in nonablative patients compared to 32% in ablative patients (hazard ratio=1.4).

116 loablative patients were at higher risk than ablative patients because of greater age, longer time fr

117 e patients given myeloablative conditioning (ablative patients) before unrelated HCT.

118 enced fewer grades III to IV toxicities than ablative patients.

119 of focused high-intensity light sources for ablative perturbation has been an important technique fo

120 nd nervous tissue, albeit with somewhat less ablative potency.

121 s (<31 days) were not improved by the use of ablative procedures (0.3% vs. 0.4%, odds ratio [OR] 0.94

122 r nonhealing facial erosions occurring after ablative procedures (carbon dioxide laser resurfacing or

123 e performed at least 6 months after lamellar ablative procedures and at least 3 months after surface

124 nt pulmonary vein isolation, with additional ablative procedures at the discretion of site investigat

125 harvesting significant numbers of LNs during ablative procedures for pathological evaluation.

126 e disease than TDSRF alone, as an adjunct to ablative procedures for the treatment of advanced Coats

127 eater utilization of partial nephrectomy and ablative procedures has increased the incidence of patie

128 Energy based ablative procedures have triggered considerable interest

129 document highlights that, while stereotactic ablative procedures such as cingulotomy and capsulotomy

130 rpative laparoscopic partial nephrectomy and ablative procedures such as cryoablation, radiofrequency

131 ce of side-effects associated with bilateral ablative procedures, alternative approaches were explore

132 atients who have nonhealing wounds following ablative procedures, EPD is challenging to treat and may

133 ocedures and at least 3 months after surface ablative procedures.

134 ts support the hypothesis that the favorable ablative properties of protein-targeting wavelengths res

135 accumulated in humans regarding stereotactic ablative radiation (SABR) therapy, a favorable option fo

136 adiation therapy (SBRT) is generally a tumor-ablative radiation modality using essential technologies

137 Recent studies have shown that local ablative radiation of established tumors can lead to inc

138 ch extrinsic resistance develops after local ablative radiation that relies on the immunosuppressive

139 In vivo LOFU followed by ablative radiation therapy (RT) results in primary tumor

140 es in 101 patients treated with stereotactic ablative radiation therapy from 2005 to 2013 were analyz

141 This radioprotection enables ablative radiation therapy in a mouse model of pancreati

142 ith noninvasive, acoustic immune priming and ablative radiation therapy to generate an in situ tumor

143 ly cured by surgery alone or surgery plus an ablative radiation therapy.

144 imaging and noninvasive delivery of precise ablative radiation with stereotactic body radiation ther

145 NIS has been exploited for over 75 years in ablative radioiodine (RAI) treatment of thyroid cancer,

146 patients with thyroid carcinoma at the first ablative radioiodine therapy.

147 onale and clinical data for both sterotactic ablative radiotherapy (SABR) and targeted therapies, and

148 Stereotactic ablative radiotherapy (SABR) for inoperable stage I NSCL

149 bectomy, sublobar resection, or stereotactic ablative radiotherapy (SABR) from January 1, 2003, throu

150 pare organs at risk (OARs) when stereotactic ablative radiotherapy (SABR) is delivered to treat centr

151 e aimed to assess the effect of stereotactic ablative radiotherapy (SABR) on survival, oncological ou

152 The application of stereotactic ablative radiotherapy (SABR) to hepatocellular carcinoma

153 with all metastases amenable to stereotactic ablative radiotherapy (SABR).

154 Rationale: When stereotactic ablative radiotherapy is an option for patients with non

155 ing in patients with NSCLC when stereotactic ablative radiotherapy is an option.

156 h ionizing radiation (primarily stereotactic ablative radiotherapy) is accumulating.

157 at a higher risk of toxicity from high-dose ablative radiotherapy.

158 ed to predict the response to incisional and ablative refractive surgery and will also affect the for

159 The ablative regimens included: (1) thiotepa (TT)/cyclophosp

160 report that reduction of tumor burden after ablative RT depends largely on T-cell responses.

161 Ablative RT dramatically increases T-cell priming in dra

162 We show that ablative RT increases intratumoral production of IFN-bet

163 Although ablative RT reduced complications from local tumor progr

164 received oral FG-4592 or vehicle control +/- ablative RT to a cumulative 75 Gy administered in 15 dai

165 We further demonstrate that ablative RT-initiated immune responses and tumor reducti

166 echnology allow for the use of high-dose (or ablative) RT to target local tumors, with limited damage

167 In the 1960s, ablative stereotactic surgery was employed for a variety

168 ssing the benefits of de-novo ICD placement, ablative strategies and other prophylactic and therapeut

169 atrial fibrillation, the outcomes of initial ablative strategies comprising either stand-alone PVI (P

170 ng, biomarkers, pharmacological therapy, and ablative strategies for AF.

171 e important implications for both pacing and ablative strategies for the prevention of initiation of

172 The addition of ablative superficial venous surgery to this strategy has

173 ts requiring midface reconstruction have had ablative surgery for malignant disease, and most require

174 obotic-assisted, ureteral reconstructive and ablative surgery is being performed routinely for both b

175 The current standard care is ablative surgery of malignant neoplasm, followed by tong

176 non-recoverable loss of muscle fibers due to ablative surgery or severe orthopaedic trauma, that resu

177 iltrative endometriosis undergoing CO2 laser ablative surgery with bowel resection (study group, 76/2

178 atment of glaucoma patients undergoing laser ablative surgery, and makes recommendations to improve c

179 Advances in minimally invasive ablative surgical approaches have led to the development

180 ot inferior to that of patients receiving an ablative TBI-based regimen.

181 A focal ablative technique called irreversible electroporation (

182 Radiofrequency ablation is the best ablative technique for the treatment of small hepatocell

183 versible electroporation (IRE), a nonthermal ablative technique, may prolong survival of patients wit

184 technical considerations for this particular ablative technique.

185 Apart from extirpative treatment, ablative techniques are becoming more popular to minimiz

186 rd diagnosis of smaller renal masses, energy ablative techniques are being increasingly utilized as p

187 Results obtained with energy ablative techniques are encouraging.

188 Energy-based tumor ablative techniques are under development for the minima

189 ts related to the modern surgical and energy ablative techniques for renal cell carcinoma.

190 Ablative techniques include pallidotomy, thalamotomy, an

191 Oncological effectiveness of ablative techniques is encouraging as 3-year data are em

192 l, largely because thermal and photochemical ablative techniques often leave foci of intestinal metap

193 culprit arrhythmia using pharmacological or ablative techniques result in symptom resolution and rec

194 These ablative techniques should be reserved for carefully sel

195 uld be managed with surgical treatment, with ablative techniques, or with watchful waiting with activ

196 aging program that offers both resection and ablative techniques.

197 of the PVs and can be effectively treated by ablative techniques.

198 ith contraindications to other commonly used ablative techniques.

199 rcinoma (HCC) who are ineligible for thermal ablative techniques.

200 -term (5 years and greater) outcome data for ablative technologies accumulate, we are likely to see a

201 roscopic and percutaneous minimally invasive ablative technologies are being increasingly employed in

202 Encouraging long-term data for ablative technologies are emerging.

203 the basis of these studies, it is clear that ablative technologies can be effective treatments for se

204 However, as ablative technologies evolve to circumvent this stalemat

205 Advances in surgical and ablative technologies have contributed to a decrease in

206 Several energy ablative technologies, currently being tested in clinica

207 cancers has led to the development of energy ablative technologies, which are less invasive alternati

208 Laser powers of 3 and 6W achieved ablative temperatures of more than 50 degrees C.

209 e in tumor temperature, from 37 degrees C to ablative temperatures of more than 50 degrees C.

210 al approach with drug-eluting microspheres), ablative therapies (such as chemical [ethanol or acetic

211 anol or acetic acid injection]), and thermal ablative therapies (such as radiofrequency ablation, las

212 acteristics and, as outcomes data mature, to ablative therapies and active surveillance.

213 HIFU is often used for ablative therapies and must be adapted to produce unifor

214 for small renal masses confirmed malignant, ablative therapies are an option in elderly patients, wh

215 e cancer survivors treated with radiation or ablative therapies are at risk for urethral stricture fo

216 an be continued beyond progression and local ablative therapies can be used to target sites of oligop

217 Locoregional transcatheter and ablative therapies continue to be used mostly for pallia

218 Elimination of B-cell ablative therapies did not result in an increased incide

219 Ablative therapies extend the capability of delivering p

220 r locoregional and metastatic disease, local ablative therapies for metastases, and palliative chemot

221 lamic nucleus (STN-DBS) has largely replaced ablative therapies for Parkinson's disease.

222 ancer, the most interesting findings concern ablative therapies for primary and recurrent prostate ca

223 t widely used locoregional transcatheter and ablative therapies for solid malignancies.

224 ext, and the use of novel minimally invasive ablative therapies has been proposed.

225 Ablative therapies have been increasingly utilized in th

226 her innovative, relatively noninvasive local ablative therapies have been introduced and have been sh

227 Focal ablative therapies have been primarily used for local tu

228 immunological responses to radiotherapy and ablative therapies in patients with metastatic prostate

229 Ablative therapies may lead to buried metaplasia in a sm

230 nterpreting the short-term results of energy ablative therapies monitored by imaging only.

231 Endoscopic surveillance after any of the ablative therapies still appears to be necessary.

232 mpatible kidney transplantation using B-cell ablative therapies such as anti-CD20 and splenectomy.

233 resection, liver transplantation, and local ablative therapies such as radio frequency ablation offe

234 resection, liver transplantation, and local ablative therapies such as radiofrequency ablation offer

235 Ablative therapies, as well as endoscopic mucosal resect

236 Unlike alternative ablative therapies, electroporation does not affect the

237 cell pool in patients recovering from T cell ablative therapies, HIV patients under highly active ant

238 and bladder neck contractures resulting from ablative therapies.

239 nd may participate in resistance to androgen-ablative therapies.

240 o improve the efficacy and/or specificity of ablative therapies.

241 ikely to be candidates for surgical or local ablative therapies.

242 ssion and potentiate the effects of standard ablative therapies.

243 ver resection (HR, 0.38; 95% CI, 0.28-0.52), ablative therapy (HR, 0.63; 95% CI, 0.52-0.76), and tran

244 therapy may be more effective than androgen-ablative therapy alone in the treatment of prostate canc

245 Despite the current success of ablative therapy and implantable defibrillators, the nee

246 prostate cancer patients undergoing androgen ablative therapy and mediates growth of androgen-insensi

247 prostate cancer patients undergoing androgen-ablative therapy because of the activation of cellular p

248 ieve either rate or rhythm control, curative ablative therapy directed at the underlying tachycardia

249 assessment of this technology as a potential ablative therapy for a number of organs and disease proc

250 an application of this technology to thermal ablative therapy for cancer is described.

251 t loss of dysplasia in patients treated with ablative therapy for HGD/intramucosal cancer.

252 ough initial treatment strategies focused on ablative therapy for threshold ROP, earlier treatment fo

253 ue to identify atrial reentrant circuits for ablative therapy guidance.

254 ment of biologically indolent cancers, focal ablative therapy has been introduced as an alternative t

255 Percutaneous local ablative therapy has proved very effective.

256 en an explosion in the literature describing ablative therapy in Barrett's esophagus.

257 timing and patient selection for endoscopic ablative therapy in Barrett's esophagus.

258 ectroanatomic characteristics and outcome of ablative therapy in consecutive patients with (1) RV dil

259 The role of ablative therapy in patients with MVR is not yet establi

260 a rationale for a systematic study on B-cell ablative therapy in patients with sarcoidosis.

261 ption, and it is primarily used as a radical ablative therapy in the treatment of soft-tissue tumors

262 igorous follow-up of all patients undergoing ablative therapy is required.

263 ico definition, active surveillance or focal ablative therapy may be a rational alternative to surgic

264 esidue in conjunction with existing androgen-ablative therapy may be more effective than androgen-abl

265 Endoscopic ablative therapy may provide clinicians an attractive al

266 casionally be identified, and (3) aggressive ablative therapy provides long-term VT control.

267 cm and no extension beyond the liver, use of ablative therapy significantly increased during 2000-201

268 The longest-term outcomes of probe-ablative therapy with cryoablation and radiofrequency ab

269 Each trial tested the hypothesis that ablative therapy would result in better clinical or angi

270 n to HG-IEN/BAc, and strict surveillance (or ablative therapy) is advisable in cases with endoscopic

271 In 105 patients, PVI was the sole ablative therapy, 49 (46.7%) of those patients remained

272 d angiography/embolization, resection, local ablative therapy, and liver transplantation.

273 patients likely to benefit from resective or ablative therapy, and perhaps prevent invasive intervent

274 ablation are the two most utilized forms of ablative therapy, and the most mature.

275 ular cancer after hepatic resection or local ablative therapy, compared with controls, participants r

276 h Barrett's esophagus-related LGD undergoing ablative therapy, radiofrequency ablation should be used

277 benefit most from intensive surveillance or ablative therapy.

278 h Barrett's esophagus, both before and after ablative therapy.

279 ged 25 years or older, who were eligible for ablative therapy.

280 recurrence after hepatic resection or local ablative therapy.

281 alignancy and responds initially to androgen ablative therapy.

282 imaging, image-guidance systems, catheters, ablative tools, and drug delivery systems.

283 of ablative intravenous busulfan (IV-BU) vs ablative total body irradiation (TBI)-based regimens in

284 e older, and had more often failed preceding ablative transplantations and cytotoxic therapies, they

285 derwent intraoperative RetCam FA and retinal ablative treatment and who had more than 3 months of fol

286 asound test results confirmed the success of ablative treatment for most patients.

287 r data is needed on long-term outcomes after ablative treatment in HIV-infected women.

288 The role of pulmonary vein (PV) isolation in ablative treatment of atrial fibrillation (AF) has been

289 pted curative radiotherapy options including ablative treatment of oligometastases (n <= 5).

290 t 15 years have greatly improved outcomes in ablative treatment of tachyarrhythmias in children.

291 l or unilateral prostate cancer, a number of ablative treatment options for focal therapy are availab

292 lateral prostate cancer lesions, a number of ablative treatment options for focal therapy are availab

293 rrences after ALPPS was amenable to surgical/ablative treatment, median CSS was significantly superio

294 However, the results of commonly performed ablative treatments (cholecystectomy and sphincterotomy)

295 We review recent literature regarding focal ablative treatments of SRMs.

296 Local ablative treatments such as ethanol injection can length

297 tomographic imaging, and (3) the efficacy of ablative treatments that result in the curative depletio

298 Needle and probe-based ablative treatments will continue to play an important r

299 Ablative treatments, including Nd:YAG laser, photodynami

300 er survivors who have undergone radiation or ablative treatments.